Log in

NASDAQ:MRUS - Merus Stock Price, Forecast & News

$12.40
-0.41 (-3.20 %)
(As of 03/29/2020 01:30 AM ET)
Today's Range
$12.40
Now: $12.40
$12.88
50-Day Range
$11.34
MA: $16.29
$19.44
52-Week Range
$11.10
Now: $12.40
$20.95
Volume22,604 shs
Average Volume54,103 shs
Market Capitalization$359.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
Merus logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.13 million
Book Value$5.61 per share

Profitability

Net Income$-55,150,000.00
Net Margins-177.15%

Miscellaneous

Employees98
Market Cap$359.60 million
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.


Merus (NASDAQ:MRUS) Frequently Asked Questions

How has Merus' stock been impacted by COVID-19 (Coronavirus)?

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRUS stock has decreased by 14.7% and is now trading at $12.40. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Merus.

What price target have analysts set for MRUS?

4 brokers have issued 1-year price targets for Merus' stock. Their forecasts range from $20.00 to $25.00. On average, they anticipate Merus' share price to reach $23.25 in the next twelve months. This suggests a possible upside of 87.5% from the stock's current price. View analysts' price targets for Merus.

Has Merus been receiving favorable news coverage?

News stories about MRUS stock have trended very negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merus earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutMerus.

Are investors shorting Merus?

Merus saw a decrease in short interest during the month of February. As of February 14th, there was short interest totaling 368,500 shares, a decrease of 15.6% from the January 30th total of 436,600 shares. Based on an average daily volume of 76,600 shares, the days-to-cover ratio is currently 4.8 days. Currently, 2.0% of the shares of the company are sold short. View Merus' Current Options Chain.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (13.54%), EcoR1 Capital LLC (7.34%), Driehaus Capital Management LLC (6.13%), Platinum Investment Management Ltd. (0.73%), Oxford Asset Management LLP (0.22%) and Old West Investment Management LLC (0.11%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View institutional ownership trends for Merus.

Which institutional investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, and Tower Research Capital LLC TRC. View insider buying and selling activity for Merus.

Which institutional investors are buying Merus stock?

MRUS stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Driehaus Capital Management LLC, Oxford Asset Management LLP, Platinum Investment Management Ltd., Old West Investment Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, and Acadian Asset Management LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Merus.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $12.40.

How big of a company is Merus?

Merus has a market capitalization of $359.60 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe. View additional information about Merus.

What is Merus' official website?

The official website for Merus is http://www.merus.nl/.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel